Loading Events

Following the Healthcare Dollar

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Share Post:

Strengthen Your Customer Connections

Understanding the world prescribers are living in allows for more meaningful customer interactions. MAP Training Programs build your knowledge on marketplace trends impacting providers and the pharmaceutical industry today. 

Begin learning today

Achieve Company Goals

Bring teams up-to-speed on the latest market access trends impacting their unique selling environment.

View custom training solutions

Keep Your Finger on The Pulse

Subscribe to the Marketplace Blog to stay up-to-date on the latest trends impacting pharma

*required





    Privacy Guaranteed — We will never share your info

    Marketplace Blog

    Trends in the Marketplace

    The Increasing Exploitation of Patient Assistance Programs

    Copay accumulator programs have only one purpose; increase profits for payers. Patients don’t gain an advantage, nor do manufacturers. On top of that, providers face the difficulty of helping patients manage a process they don’t understand. And somehow, the whole concept has gotten worse. Patient Assistance Programs offered by manufacturers are intended to relieve the patient’s financial burden when filling their prescription. From the patient perspective, this is great. This blog takes a closer look behind the curtains to reveal

    Fractures in The 340B Program

    The 340B Program remains controversial. Hospitals and other Covered Entities (providers qualified to buy drugs at 340B prices) that benefit from the program describe it as a lifeline that keeps them in business. Pharma sees 340B as a program that has grown well beyond its original purpose, and at their expense. This controversy has created fracture lines that run in many different directions. The fractures are being created by lawsuits, government regulations, federal law, and other factors. We’ll describe the

    The Impact of Medicare Price Negotiations

    The Inflation Reduction Act (IRA) passed on August 16th, 2022 brings big changes for the pharmaceutical industry. On August 31st we had a live discussion on the law’s anticipated impact. Here is a summary of our discussion: Inflation Penalty The intent of the law is to impose penalties on manufacturers who raise drug prices faster than inflation. Penalties will begin very soon; however, recent Consumer Price Index (CPI) inflation rates allow increases of around 13.5% without any penalties assessed. Manufacturers

    Purchasing the Program does not automatically enroll you in a live discussion session. After creating your ProFusion MAP account, you can select a live discussion session to attend. Attendance for each session is capped at 10 participants.

    All Available Sessions

    There are no upcoming events at this time

    Stay Updated on New MAP Programs and Dates

    As the market access environment changes, relevant topics will be covered through new programs. Subscribe below to be the first to know about new MAP Program topics and added dates for existing Programs.

    *required





      Privacy Guaranteed — We will never share your info!

      Manufacturers Restricting 340B Sales to Contract Pharmacies

      • Abbvie
      • Amgen
      • AstraZeneca
      • Boehringer Ingelheim
      • Eli Lilly
      • Merck
      • Novartis
      • Novo Nordisk
      • Sanofi
      • UCB
      • United Therapeutics
      • and more…